Stay One Step Aheadof Diabetes

With the Performance and Protection that Dexcom Continuous Glucose Monitoring Offers

Introducingthe only CGMapproved for kids as young as 2 years old

Dexcom is the only Continuous Glucose Monitoring (CGM)

system that puts you and your patients One Step Ahead of

diabetes. Dexcom combines accuracy, consistency and reliability

to give you and your young patients the confidence to make healthy,

well-informed decisions with a CGM you can trust.

The New Standard in Glucose Monitoring is Here Today

Tickled Pink

Classic Black

Ocean Blue

Dexcom is the only Continuous Glucose Monitoring (CGM)

system that puts you and your patients One Step Ahead of

diabetes. Dexcom combines accuracy, consistency and reliability

to give you and your young patients the confidence to make healthy,

well-informed decisions with a CGM you can trust.

The New Standard in Glucose Monitoring is Here Today

Tickled Pink

Classic Black

Ocean Blue

Only CGM gives your patients and their caregivers the continuous data they need to

Stay One Step Ahead of Diabetes

< 4 days/week sensor use

4 < 6 days/week sensor use

6 or more days/week sensor use

Age 8-14 Age 15-24 Age 25+

n = 7n = 21

n = 28

0.2

0.1

0

-0.1

-0.2

-0.3

-0.4

-0.5

-0.6

-0.7

-0.8

P < .001

n = 10

n = 29

n = 17

P = .002

n = 1

n = 6

n = 43

P = .02

Ch

ang

e in

A1c

(%

)

Sustained Benefits Over Time2

Not only will your patients achieve their glycemic goals with CGM, sustained reduction in A1C is attained with continued use and shows the importance of CGM as a necessary tool in optimal glucose management.

0

-0.2

-0.4

-0.6

-0.8

-1

-1.2

Ch

ang

e in

A1c

(%

)

Age 8-14 Age 15-24 Age 25+

N = 3 N = 6

-0.5 -0.5-0.5

-0.7

-1.0

-0.8

0-26 weeks

0-52 weeks

N = 15

0

-0.2

-0.4

-0.6

-0.8

-1

-1.2

Ch

ang

e in

A1c

(%

)

Age 8-14 Age 15-24 Age 25+

N = 3 N = 6

-0.5 -0.5-0.5

-0.7

-1.0

-0.8

0-26 weeks

0-52 weeks

N = 15

Substantial Decrease in A1C1 Young patients and their caretakers are faced with the constant challenge of maintaining tight glycemic control. But a common side effect of intensive diabetes management is hypoglycemia.

A JDRF study showed how using a CGM system, such as the Dexcom G4 PLATINUM, for at least 6 days a week can lead to significant decreases in A1C, enabling patients to reach their glycemic goals without an increased risk of hypoglycemia.

CGM use (6 or more days/week) results in significant decreases in A1C across child, adolescent, and adult age groups

CGM benefits are sustained over time, demonstrating the importance of CGM in glucose management.

1 Battelino T et al. Effect of Continuous Glucose Monitoring on Hypoglycemia in type 1 diabetes. Diabetes Care, Vol. 34, April 2011.

2 The JDRF CGM Study Group. Diabetes Care, Vol. 32, Number 11, November 2009.

CGM FirstGlucose management is key to helping young patients understand what’s going on in their body. Injections and insulin pumps are delivery mechanisms that lack the insight your patient needs to know where their glucose status is. With CGM, not only will your patients see where their glucose is and where it’s headed, they can better optimize insulin delivery regardless of how they choose to deliver their insulin.

The Deiss study below shows significant reductions in A1C by those using injections or insulin pumps to manage their diabetes.3 With CGM, patients can see their glucose levels, make appropriate decisions, and stay ahead of their glucose curve.

Continuous Group (arm 1)

Bi-weekly Group (arm 2) - 3-day periods every 2 weeks

Control Group - Conventional SMBG

10

9.5

9

8.5

8

Baseline 1 Month 3 Months

Hb

A1c

(%

)

P = .008 P = .003

Fig. X: Deiss study of pumpers and injectors (50/50 children/adults; 52/48 CSII/MDIs)Continuous Group (arm 1)

Bi-weekly Group (arm 2) - 3-day periods every 2 weeks

Control Group - Conventional SMBG

10

9.5

9

8.5

8

Baseline 1 Month 3 Months

Hb

A1c

(%

)

P = .008 P = .003

Fig. X: Deiss study of pumpers and injectors (50/50 children/adults; 52/48 CSII/MDIs)

Consensus Statement, Pediatric Diabetes (2012)4

This consensus statement has been developed by a world-wide expert panel of pediatric endocrinologists and represents the clinical guidance of the use of continuous glucose monitoring from the European Society for Pediatric Endocrinology, the Pediatric Endocrine Society and the International Society for Pediatric and Adolescent Diabetes. Use of real-time CGM provides the following benefits:

Improved overnight control with hypoglycemia alarms

Enhanced understanding of diabetes management teaching

Improved daytime bolus dosing with trend arrows and hyper- and hypoglycemia alarms for real-time adjustments

Improved management of acute illnesses

Insulin injectors and pumpers benefit from decrease in A1C with real-time CGM.

Improvements attained without an increase in daily insulin dose.

2 The JDRF CGM Study Group. Diabetes Care, Vol. 32, Number 11, November 2009.

3 Deiss D. et al. Improved Glycemic Control in Poorly Controlled Patients with Type 1 Diabetes using Real-Time Continuous Glucose Monitoring.

4 Phillip M, Danne T, Shalitin S, Buckingham B, Laffel L, Tamborlane W, Battelino T and Consensus Forum Participants. Pediatric Diabetes, 2012.

No matter where, when, and how your patients wear it, the G4 PLATINUM offers exceptional performance and accuracy along with features to fit your young patient’s active lifestyle.5

Overall

By Placement6

[MARD % vs. SMBG]

Abdomen

Buttocks

15.3%

14.4%

16.2%

Overall Day

By Time of Day7

[MARD % vs. SMBG]

Overall Night

15.6%

14.1%

Preschool (2-5)

By Age5

[MARD % vs. SMBG]

Child (6-12)

Adolescent (13-17)

16.6%

15.8%

14.3%

Underweight

By Weight5

[MARD % vs. SMBG]

Healthy Weight

17.2%

15.6%

Overweight

Obese

15.3%

14.5%

Control and ConvenienceWithout Compromise

Our Customer Loyalty Comes from our Performance and Wearability

• PediatricpatientsandtheircaregiversrealizethevalueoftheG4PLATINUMthesecondtheyputiton

• TheG4PLATINUMisdesignedtofitintopediatricpatients’lifestyles

• ThequalityofourCGMhaskeptitrankedconsistentlyhighestincustomerloyaltyandusersatisfactionfor 4 consecutive years, per independent research results8

20102009 2011 2012

5 Effectiveness and Safety of the Dexcom Continuous Glucose Monitoring System in Pediatrics with Diabetes Mellitus Clinical Study Report. 2013.6 Laffel et al. Performance of a CGM System and CGM Glucose Ranges in Youth Ages 2-17 Years Old. Abstract and Oral Presentation at the 39th Annual International Society of Pediatric and Adolescent Diabetes, Gothenburg, Sweden, October, 2013.7 Buckingham, B. Presented at the 6th Annual International Conference on Advanced Technologies and Treatments for Diabetes.

8 dQ&A market research, 2009-2012

1.5”

1.8”

4.0”

0.5”

Tones/Melodies Alert profiles with a choice of tones and melodies to suit your patients’ individual needs. Severe hypo alarm at 55mg/dL for added awareness no other CGM provides.

20-Feet Range9 3X farther than the next available brand with 95% of expected sensor data captured.

Sensor Longest life and smallest sensor by volume for comfortable, easy wear.

Dexcom G4 PLATINUMTake a Closer Look

Color TrendsVivid colors in red, yellow and white to easily read and identify glucose highs and lows

Easy Calibration 2 calibrations/day for optimal accuracy

Touch of a Button™ Glucose trend on demand – everything you need to see with one button.

Trend Arrows and Rate-of-Change (ROC) Alerts Catch highs and lows before they happen

Transmitter/sensor pod is water resistant for up to 8 feet for 24 hours

9 Dexcom G4 PLATINUM (Pediatric) User Guide, 2013.

Nighttime Range

Dexcom STUDIOTM

CGM Software and Reports

Dexcom PORTRAITTM

A Summary Report That Says It All

Customizable •Overall,pre-meal,post-mealandnighttimetargetglucoseranges

•QuickPrintTM preferred reports

Comprehensive •Sevenpatternreportsincludingonepagesummaries,statisticsanddailyglucosetrends

Efficient •SummaryReports •Quickdownloads

FocusedFocuses on issues of hypoglycemia and

hyperglycemia during day and night

IntuitiveVisually identifies theclincally significant issuesbased on the frequency,duration, and intensity of hypoglycemia andhyperglycemia

SimplifiedOne page summary reportthat identifies and prioritizes the clinical issues and

provides potential solutions

While studies have shown that wearing a CGM at least 6 days/week yields benefits, the challenge faced by practitioners is how to ensure patient compliance. At Dexcom, we recognize that the only CGM that matters is the one patients will wear which is why we designed the Dexcom G4 PLATINUM with you and your patients in mind. Check it out:

Longest Wear Sensor9

The only sensor on the market approved for 7 days - longer than other CGM brands - making weekly sensor changes convenient and easy to remember.

Low Variability9

Minimal variability of 7% between sensors which leads to consistent performance.

Toddler SuitableDexcom G4 PLATINUM is the only CGM approved for use in

children as young as 2 years old.

Placement Choice Placement is approved for abdomen or upper

buttocks to comfortably accommodate kids’ active lifetyle

Customer Loyalty10,11 90% of Dexcom users are happy and satisfied with their G4 PLATINUM CGM

Highest Adherence12 2x more Dexcom customers stay on their CGM than any other brand CGM users.

Not Just Any CGM.It’s a Dexcom CGM.

9 Dexcom G4 PLATINUM (Pediatric) User Guide, 2013.10 dQ&A market research, 2009-201211 Dexcom internal data on file, 201212 dQ&A market research, 2013

CGM is covered by the majority of commercial insurance companies*

•Over 98% of commercially insured type 1 patients have coverage for CGM13 •CGMcoveragefortype2patientsoninsulinhasmorethantripled in the last 2 years alone13

Patients and physicians can receive guidance and support for access, coverage, and reimbursement issues regarding the Dexcom G4 PLATINUM CGM system.

Verifying Insurance Coverage

* Each payor and plan has their own set of criteria that must be met. Dexcom can provide information on current coverage decisions.

A dedicated staff of Certified Diabetes Educators (CDEs) is available to support you, your patients, and their caregivers for a positive and successful CGM on-boarding experience. However your practice conducts patient training — whether inside or outside the office — you can rely on DexcomCARE to be there with support you need.

Dexcom’s Got Your Patients Covered24/7 support for caregivers and their children so they can stay One Step Ahead of diabetes

13 Dexcom internal data on file, 2013

Onboarding Patients

Customer Support Help with first-time orders, re-orders, tracking shipments, and locating a local Dexcom representative.

Email: CustomerService@dexcom.com

Technical SupportAssistancewithquestionsregardingCGMuseandtroubleshootingissues.**

Email: TechSupport@dexcom.com

**DexcomTechnicalSupportdoesnotoffermedicaladvice.

Our support teams are here to assist youand your patients every step of the way.

Call toll-free 1-888-738-3646.

BRIEF SAFETY STATEMENTThe Dexcom G4 PLATINUM (Pediatric) Continuous Glucose Monitoring System is a glucose monitoring device indicated for detecting trends and tracking patterns in persons (age 2 to 17 years) with diabetes. CONTRAINDICATIONS: Remove the System before MRI, CT scan, or diathermy treatment. Taking acetaminophen while wearing the sensor may falsely raise your sensor glucose readings. WARNING: Do not use the System for treatment decisions. The System does not replace a blood glucose meter. In a pediatric clinical study, larger differences were observed between this CGM device and actual blood glucose values compared to those differences observed in the adult clinical study. Use your blood glucose meter for treatment decision. In a pediatric clinical study, a significant number of low glucose events were not detected by CGM. Do not rely solely on CGM alerts to detect low glucose. If a sensor breaks and no portion of it is visible above the skin, do not attempt to remove it. Seek professional medical help if you have infection or inflammation. Report broken sensors to Dexcom Technical Support. The System is not approved for use in pregnant women or persons on dialysis. Sensor placement is not approved for sites other than under the skin of the belly or upper buttocks. Contact Dexcom Toll Free at 877-339-2664 or www.dexcom.com for detailed indications for use and safety information.

Dexcom, Dexcom G4, Dexcom G4 PLATINUM, One Step Ahead, Dexcom SHARE, Touch of a Button, DexcomCARE, My Dexcom Day and Sharing is Caring are either registered trademarks or trademarks of Dexcom, Inc. in the United States and/or other countries. All trade dress used in connection with Dexcom products and services appearing herein are property of Dexcom and protected by United States and foreign trademark laws. All other product or company names that may be mentioned in this publication are tradenames, trademarks or registered trademarks of their respective owners.

@2013 Dexcom, Inc. All rights reserved

Customer Care:

(888) 738-3646

Dexcom Inc. | Corporate Headquarters

6340 Sequence Drive

San Diego, CA 92121

(858) 200-0200

www.dexcom.com

LBL012357 Rev01 MT22533